| David Sarcu, MD | |
|
1221 N Highland Ave, Aurora, IL 60506-1404 | |
| (630) 859-8700 | |
| Not Available |
| Full Name | David Sarcu |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 13 Years |
| Location | 1221 N Highland Ave, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467740217 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0123X | Otolaryngology - Facial Plastic Surgery | 036.142619 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Delnor Community Hospital | Geneva, IL | Hospital |
| Copley Memorial Hospital | Aurora, IL | Hospital |
| Presence Mercy Medical Center | Aurora, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Scientists at the University of California, San Diego have developed a new method for making scaffolds for culturing tissue in three-dimensional arrangements that mimic those in the body. This advance, published online in the journal Advanced Materials, allows the production of tissue culture scaffolds containing multiple structurally and chemically distinct layers using common laboratory reagents and materials.
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants.
Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.
Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.
› Verified 7 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003542184 PECOS PAC ID: 7810800935 Enrollment ID: O20220930002728 |
News Archive
Scientists at the University of California, San Diego have developed a new method for making scaffolds for culturing tissue in three-dimensional arrangements that mimic those in the body. This advance, published online in the journal Advanced Materials, allows the production of tissue culture scaffolds containing multiple structurally and chemically distinct layers using common laboratory reagents and materials.
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants.
Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.
Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Sarcu, MD 1221 North Highland Avenue, Aurora, IL 60506 Ph: () - | David Sarcu, MD 1221 N Highland Ave, Aurora, IL 60506-1404 Ph: (630) 859-8700 |
News Archive
Scientists at the University of California, San Diego have developed a new method for making scaffolds for culturing tissue in three-dimensional arrangements that mimic those in the body. This advance, published online in the journal Advanced Materials, allows the production of tissue culture scaffolds containing multiple structurally and chemically distinct layers using common laboratory reagents and materials.
Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere's proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants.
Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.
Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.
› Verified 7 days ago
Robert J Nudera, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 2040 Ogden Ave, Suite 301, Aurora, IL 60504 Phone: 630-978-6895 Fax: 630-375-2905 | |
Dr. Sanjiv Upadhyay, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2040 Ogden Ave, Suite 301, Aurora, IL 60504 Phone: 630-978-6895 Fax: 630-753-2905 | |
Stephen M Kelanic, M.D., F.A.C.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2040 Ogden Ave Ste 301, Aurora, IL 60504 Phone: 630-978-6895 Fax: 630-375-2905 | |
Michael C Loebach, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 | |
Richard L Kersch, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 | |
Michael Eggerstedt, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2040 Ogden Ave Ste 301, Aurora, IL 60504 Phone: 630-978-6895 |